ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
8 announcements with these filters
Gujarat Themis Biosyn Limited acquired MicroBiopharm Japan Co. Ltd. for approximately ₹1,300 Crore. This acquisition expands its pharmaceutical CDMO capabilities.
GTBL completed 100% acquisition of MBJ Japan for JPY 21.5 billion (~₹1,333 Cr). The deal adds three GMP plants and precision fermentation capabilities.
Gujarat Themis Biosyn is acquiring MicroBiopharm Japan for ₹1,300 Crore to expand its CDMO capabilities. This strategic move strengthens its position in precision fermentation and biotechnology.
Gujarat Themis Biosyn Limited will acquire 100% of Japan-based MicroBiopharm Japan for ₹1,290 Crore. This strategic acquisition expands GTBL's CDMO capabilities into advanced precision fermentation.
Gujarat Themis Biosyn Limited is acquiring 13 established branded generic products from Sanofi for €158 million (₹1,722.2 Crore). The acquisition covers 55 countries across Europe, Middle East, and Africa. This strategic move strengthens GTBL’s global anti-infective platform and provides access to regulated markets without acquiring manufacturing facilities or employees.
Gujarat Themis Biosyn Limited is acquiring 13 branded generic products from Sanofi for Euro 158 million (approx. ₹1,722.2 Crore). The asset-light acquisition targets markets in Europe, Middle East, and Africa. The deal strengthens GTBL's global anti-infective platform and is expected to conclude by December 2026.
Gujarat Themis Biosyn Ltd signed an agreement to acquire Sanofi's global Anti-TB and Anti-Infective portfolio for EURO 158 million (₹1,722.20 Crore). The deal includes 13 brands across 55+ countries, enabling global forward integration into finished dosage formulations. The transaction is expected to close by Q3FY27, significantly enhancing the company's international footprint and margin profile.
Gujarat Themis Biosyn Limited has agreed to acquire 13 anti-tuberculosis and anti-infective brands from Sanofi for ₹1,722.2 Crore (Euro 158 million). The acquisition provides immediate access to regulated markets in Europe, Middle East, and Africa. The transaction is expected to close by December 2026, strengthening GTBL's global generic pharmaceuticals platform.